77 completed, 24 terminated, 23 unknown, 21 recruiting. 67 Phase 2, 45 Phase 1, 23 Not applicable, 10 Phase 3, 6 Early Phase 1.
Follow Myeloma: new trials by email Literature Review of Myeloma trials Research Report on Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 220 | 2026-12-01 | 2026-05-20 |
| REal World MAIA UK OutcomEs Myeloma | Not yet recruiting | The Royal Wolverhampton Hospitals NHS Trust | 300 | 2026-12-01 | 2026-09-15 | |
| Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies Myeloma | Not yet recruiting | Odense University Hospital | 50 | 2026-10-01 | 2026-10-16 | |
| Rutgers University Study of the Genetics of Blood Cancers Blood Cancers, Blood Cancer | Recruiting | Rutgers, The State University of New Jersey | 10000 | 2026-09-22 | 2026-10-01 | |
| Evaluation of Skin Tests in Biotherapy Allergies Drug skin tests (investigating hypersensitivity to a biotherapy) - Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms | Not applicable | Recruiting | University Hospital, Angers | 70 | 2026-06-17 | 2026-06-18 |
| CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors Dose Level -1, Dose Level 1 (starting dose level), Dose Level 2 - Lymphoma, Myeloma | Phase 1 | Withdrawn | Baylor College of Medicine | 2026-06-01 | 2026-09-16 | |
| HEME Home Transfusion Program HEME-Hospice Program - Leukemia, Myeloma | Not applicable | Recruiting | Dana-Farber Cancer Institute | 700 | 2025-09-10 | 2026-10-28 |
| Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy Home Automated Telemanagement (HAT) Patient Unit - Lymphoma, Myeloma | Not applicable | Recruiting | University of Utah | 40 | 2025-09-01 | 2026-02-05 |
| A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma Siltuximab - CRS - Cytokine Release Syndrome, Myeloma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-08-10 | 2025-08-06 |
| A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties Music Therapy/MT, Therapist-Attention Music Education/TAME Control - Blood Cancer, Lymphoma | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2025-06-27 | 2026-05-26 |
| Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma Elranatamab - Myeloma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 39 | 2025-05-27 | 2025-12-03 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) Trimethoprim / Sulfamethoxazole, Immune Globulin Intravenous - Myeloma, Non Hodgkin's Lymphoma | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-05-07 | 2025-10-07 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) Intravenous immunoglobulin, Trimethoprim / Sulfamethoxazole, Amoxicillin clavulanic acid - Myeloma, Non-Hodgkin's Lymphoma | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-05-06 | 2025-10-07 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) Trimethoprim Sulfamethoxazole, Amoxycillin/clavulanic acid, Immune Globulin Intravenous - Myeloma, Leukemia | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-05-06 | 2025-10-07 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) Immune Globulin Intravenous - Myeloma, Non Hodgkin's Lymphoma | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-04-28 | 2025-10-07 |
| Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care LLS Program - Leukemia, Lymphoma | Not applicable | Recruiting | University of Miami | 400 | 2025-02-04 | 2026-10-16 |
| Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia Myeloma, Lymphoma | Active not recruiting | Tel-Aviv Sourasky Medical Center | 250 | 2025-01-20 | 2025-07-28 | |
| Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM Elotuzumab, Iberdomide, Dexamethasone - Myeloma, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Omar Nadeem, MD | 49 | 2024-11-01 | 2026-10-07 |
| PROSpECT-PRIOR-2-CHEMO: PRIOR Dental Intervention Before Chemo to Reduce Chemotherapy Complications PRIOR [Proactive Intensive Oral Review & Treatment] - Oncology, Periodontitis | Not applicable | Not yet recruiting | University of Leeds | 60 | 2024-07-01 | 2024-06-10 |
| PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab) Tocilizumab before CAR-T cell infusion, Tocilizumab at emerging CRS - Myeloma, Lymphoma | Phase 2 | Recruiting | Insel Gruppe AG, University Hospital Bern | 100 | 2024-07-01 | 2024-07-08 |
Showing 20 of 166. Sign in to see all of them.
Neoplasms, Plasma Cell (166) · Lymphoma (62) · Leukemia (44) · Multiple Myeloma (41) · Hematologic Neoplasms (18) · Hodgkin Disease (16) · Myelodysplastic Syndromes (16) · Lymphoma, Non-Hodgkin (15) · Neoplasms (12) · Leukemia, Myeloid, Acute (11) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Graft vs Host Disease (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Anemia, Refractory, with Excess of Blasts (7) · Breast Neoplasms (5)
Neoplasms by Histologic Type (165) · Neoplasms (154) · Hemic and Lymphatic Diseases (115) · Immune System Diseases (111) · Immunoproliferative Disorders (111) · Lymphoproliferative Disorders (107) · Hematologic Diseases (93) · Lymphatic Diseases (75) · Cardiovascular Diseases (46) · Blood Protein Disorders (44) · Vascular Diseases (43) · Hemorrhagic Disorders (42) · Paraproteinemias (42) · Hemostatic Disorders (40) · Neoplasms by Site (28)
Dexamethasone (24) · Lenalidomide (17) · Bortezomib (16) · Melphalan (16) · Cyclophosphamide (13) · fludarabine (13) · Calcium Dobesilate (10) · Surveys and Questionnaires (9) · Granulocyte Colony-Stimulating Factor (8) · Busulfan (7) · Stem Cell Transplantation (7) · fludarabine phosphate (7) · Radiotherapy (6) · Filgrastim (5) · carfilzomib (5)
M.D. Anderson Cancer Center (25) · H. Lee Moffitt Cancer Center and Research Institute (5) · Memorial Sloan Kettering Cancer Center (5) · Monash University (4) · University of Chicago (4) · Case Comprehensive Cancer Center (3) · David Rizzieri, MD (3) · Insel Gruppe AG, University Hospital Bern (3) · National Cancer Institute (NCI) (3) · Baylor College of Medicine (2) · Dana-Farber Cancer Institute (2) · Duke University (2) · Fate Therapeutics (2) · Hospital Universitario Dr. Jose E. Gonzalez (2) · Nantes University Hospital (2)
United States (88) · France (22) · United Kingdom (12) · China (7) · Australia (5) · Switzerland (5) · Canada (4) · Italy (3) · Spain (3) · Denmark (2) · Germany (2) · Mexico (2) · Netherlands (2) · Norway (2) · Singapore (2)
David Rizzieri, MD (4) · Muzaffar H. Qazilbash, MD (4) · Zoe McQuilten, Professor (4) · Dolores Grosso, DNP, CRNP (2) · Ehsan Malek, MD (2) · Jatin J. Shah, MD (2) · Katell LE DU, MD (2) · Maurizio Zangari, MD (2) · Neal Flomenberg, MD (2) · Robert Orlowski, MD, PHD (2) · Yago Nieto, MD, PhD (2) · Aaron Rapoport, M.D. (1) · Adam Cohen, MD (1)
PMID 31618456, PMID 16040380, PMID 16404741, PMID 17896890, PMID 18283630, PMID 18850014, PMID 19720922, PMID 20067838, PMID 20530974, PMID 20919852, PMID 22198540, PMID 22451423, PMID 22571202, PMID 23100308, PMID 23194056, PMID 23994781, PMID 24269380, PMID 24520093, PMID 24658821, PMID 24886772, PMID 25784682, PMID 26932802, PMID 27270177, PMID 27986738, PMID 28067870, PMID 28379796, PMID 28522110, PMID 28835615, PMID 29463563, PMID 29567784, PMID 30237154, PMID 30501870, PMID 30718802, PMID 30859608, PMID 30910541, PMID 31807987, PMID 31940591, PMID 32090636, PMID 32687451, PMID 33951890, PMID 34344873, PMID 34392637, PMID 34559006, PMID 34563917, PMID 34643690, PMID 34935483, PMID 35303007, PMID 35705312, PMID 36173561, PMID 36198471
P01CA124787 (2), 2005 (1), 2009 (1), 2025 (1), P30CA006516 (1), R37CA225791 (1), R37CA289639 (1)